Ferring Pharmaceuticals Targeting Inflammatory Bowel Disease With Bacteriophage-based Therapy

Ferring Pharmaceuticals Targeting Inflammatory Bowel Disease With Bacteriophage-based Therapy
Ferring Pharmaceuticals recently initiated a new research and development collaboration with Intralytix to develop a bacteriophage-based therapy for Inflammatory Bowel Disease (IBD). InflammatoryBowel Disease (IBD) is characterized by chronic inflammation in the digestive tract (either in its entirety or focused on particular areas of the GI) and includes two major designated conditions, ulcerative colitis and Crohn’s disease. The symptoms

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *